A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in ...

Pfizer beat first-quarter profit estimates on Wednesday, benefiting from cost cuts and strong sales for its pneumonia and ...

A potential treatment for COVID-19 may have been hiding in our medicine cabinets, a new study in PNAS has found ...

Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID ...

Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and ...

Pfizer lifted its annual profit forecast on Wednesday, and reported first-quarter results that topped Wall Street estimates ...

May 1 - Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID antiviral treatment and strong demand for pneumonia vaccine, sending its ...

The U.S. drugmaker's shares rose nearly 3% before the bell after the company said it expects adjusted earnings per share of ...

told Salon via email that the research could have broader implications that extend beyond COVID-19. “This could be a potential broad spectrum antiviral treatment and prophylaxis,”Adalja said.

Pfizer’s stock price rose 6% by the end of the day Wednesday to $27.18.

W hen new pharmaceutical drugs are invented in the future, Charles Gore hopes that every drug manufacturer will ask itself: ...

Pfizer raised its annual profit forecast and reported first-quarter results that exceeded Wall Street’s expectations, driven ...